英矽智能与泰亘达成合作里程碑:授权肾病贫血候选药物ISM4808完成I期临床试验首例患者入组及给药

美股速递
Mar 06

英矽智能与泰亘生物科技的合作迎来关键进展。双方共同宣布,其授权开发的慢性肾病贫血候选药物ISM4808,已顺利完成I期临床试验的首例患者入组及首次给药。这一里程碑标志着该创新疗法正式步入人体临床验证阶段,为后续开发奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10